{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-23-000126","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.597845+00:00","generated_at":"2026-06-08T23:32:29.672378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q3 revenue $270.9M (+26.8% YoY); raises full-year revenue guidance to $1.05B-$1.07B","bullets":["Revenue $270.9M (+26.8% YoY, +25.9% constant currency); thrombectomy products revenue $179.1M (+38.0% YoY).","Income from operations $12.6M; non-GAAP income from operations $33.2M. Net income $9.2M; adjusted EBITDA $51.5M (19.0% margin).","Gross margin improved to 65.6% from 63.3% YoY, driven by favorable product mix and higher volume.","Recorded $18.2M one-time expense for acquired IPR&D; total operating expenses 60.9% of revenue.","Q4 2023 revenue growth expected 28%-31% YoY; full year 2023 revenue guidance raised to $1.05B-$1.07B."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-23-000126","json":"https://secwatch.observer/filing/0001321732-23-000126.json","markdown":"https://secwatch.observer/filing/0001321732-23-000126.md","text":"https://secwatch.observer/filing/0001321732-23-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/0001321732-23-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/pen-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:32:29.672378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3299653ae24fc16de22835686e866e74ca8b4433","claim":"Penumbra Inc reported the third quarter ended September 30, 2023 results: revenue $270.9 million, net income $9.2 million.","evidence_excerpt":"Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency 1 , compared to the third quarter of 2022. • Revenue of $179.1 million from sales of our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/0001321732-23-000126-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$270.9 million"},{"label":"Net income","value":"$9.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}